Chimeron Bio develops in vivo CAR-T therapies and cancer vaccines using self-amplifying RNA technology that enables the delivery of large RNA payloads and multiple gene expressions. This approach enhances therapeutic potency and gene expression, addressing the need for more effective and personalized cancer treatments.
Funding
$12.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often lack the specificity needed to target tumor cells effectively, leading to systemic toxicity and limited efficacy, especially for complex or metastatic cancers. Traditional cancer vaccines and immunotherapies struggle to elicit robust and sustained anti-tumor immune responses.
Solution
Chimeron Bio is developing a platform for in vivo CAR-T therapies, immuno-oncology, and cancer vaccines based on self-amplifying RNA (saRNA) technology. Their approach enables the delivery of large RNA payloads and the expression of multiple genes from a single construct, enhancing therapeutic potency and enabling multi-pathway therapeutic interventions. The saRNA platform facilitates targeted delivery and uptake, potentially improving the specificity and reducing off-target effects of cancer treatments. By delivering multiple proteins, Chimeron Bio aims to stimulate a more comprehensive and durable anti-tumor immune response.
Target Audience
The primary target audience includes researchers and clinicians focused on developing advanced cancer therapeutics, as well as pharmaceutical companies seeking innovative RNA-based technologies for oncology.
Features
- Self-amplifying RNA (saRNA) technology for enhanced and prolonged gene expression
- Capability to deliver exceptionally large RNA payloads, accommodating large or multiple proteins
- Multi-gene delivery for co-expression of multiple therapeutic proteins
- Potential for targeted delivery via customizable envelope and ligand combinations
- Development of in vivo CAR-T therapies, cancer vaccines, and immuno-oncology platforms